CD134 as target for specific drug delivery to auto-aggressive CD4+T cells in adjuvant arthritis
Elmieke P.J. Boot(Utrecht University), Marca H. M. Wauben(University of Applied Sciences Utrecht), Josée P.A. Wagenaar-Hilbers(Utrecht University), Linda A. Everse(Utrecht University), Gert Storm(Yong In University), Gerben A. Koning(Università Cattolica del Sacro Cuore), Willem van Eden(University of Applied Sciences Utrecht)
Cited by 32
Related Papers
Current Trends and Challenges in the Clinical Translation of Nanoparticulate Nanomedicines: Pathways for Translational Development and Commercialization
|Frontiers in Pharmacology|2018|937
Sheddable Coatings for Long-Circulating Nanoparticles
|Pharmaceutical Research|2007|549
MIFlowCyt‐EV: a framework for standardized reporting of extracellular vesicle flow cytometry experiments
|Journal of Extracellular Vesicles|2020|514
Overcoming Limitations in Nanoparticle Drug Delivery: Triggered, Intravascular Release to Improve Drug Penetration into Tumors
|Cancer Research|2012|458
Ligand-targeted particulate nanomedicines undergoing clinical evaluation: Current status
|Advanced Drug Delivery Reviews|2013|396